Arena Pharmaceuticals, Inc. Jan. 16 announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for APD418, a β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope, in development for the treatment of decompensated heart failure (DHF).
“With approximately 10 million DHF patient hospital visits expected in the US by 2025 and few viable treatment options, we believe that APD418 has the potential to make a significant impact for these patients,” stated Chris Cabell, MD, MHS, FACC, Arena’s Senior Vice President and Chief Medical Officer. “We are pleased with the Fast Track designation and look forward to advancing this program as part of our cardiovascular focus.”
Arena Pharmaceuticals has described APD418 as a first-in-class β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope. It is a selective antagonist designed to improve cardiac contractility with minimal effect on heart rate, blood pressure and myocardial oxygen consumption, the company said and thus potentially avoids adverse events associated with current inotrope therapies.